Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
208 stopped studies mapped to Male Reproductive System Carcinoma and descendants · 97% state a reason
Over the 208 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation… | Phase 1 / Phase 2 | suspended | Aug 28, 2019 | National Cancer Institute (NCI) | Other - To assess the study's feasibility. | Other (stated, no rule matched) |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | Phase 1 | terminated | Nov 4, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | — | withdrawn | Feb 27, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic… | Phase 2 | terminated | Feb 22, 2018 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer… | Phase 1 / Phase 2 | terminated | Nov 17, 2020 | Amgen | Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not… | Safety / toxicity |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT06200103 | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate… | Phase 2 | suspended | Jan 10, 2024 | Mayo Clinic | Pending additional funding. | Funding |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or… | Phase 2 | suspended | Aug 20, 2020 | City of Hope Medical Center | 05/26/2026 DSMC: Delinquent PMT reporting. | Other (stated, no rule matched) |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | terminated | May 15, 2017 | Wake Forest University Health Sciences | PIs not interested in continuing with the trial. | Other (stated, no rule matched) |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing… | N/A | suspended | Nov 30, 2020 | Roswell Park Cancer Institute | Protocol being updates and staff trained | Other (stated, no rule matched) |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | Phase 2 | terminated | Oct 5, 2021 | University of Utah | Lack of Funding | Funding |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in… | Phase 2 | suspended | Apr 15, 2020 | Ivan de Kouchkovsky, MD | Due to funding | Funding |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients… | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Corcept Therapeutics | The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the… | Enrollment / accrual |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Jan 20, 2021 | Thomas Hope | Low accrual | Enrollment / accrual |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer… | Phase 2 | terminated | Jul 24, 2019 | University of California, Davis | PI choice; poor accrual | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone… | Phase 2 | withdrawn | Jun 17, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05362032 | Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted… | N/A | suspended | May 5, 2022 | OHSU Knight Cancer Institute | Study team paused enrollment | Enrollment / accrual |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | Early Phase 1 | withdrawn | Jul 7, 2025 | Thomas Hope | Sponsor funding | Funding |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Phase 2 | terminated | Oct 20, 2022 | Partner Therapeutics, Inc. | Merus terminated the study early due to changes in organizational priorities. | Other (stated, no rule matched) |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant,… | Phase 1 / Phase 2 | terminated | Sep 21, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib… | Other (stated, no rule matched) |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant…(DICE) | Phase 2 | terminated | Mar 11, 2019 | Cancer Trials Ireland | Insufficient accrual | Enrollment / accrual |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | Phase 1 | terminated | Apr 21, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic… | Phase 2 | terminated | Dec 4, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With…(CELLO-1) | Phase 1 / Phase 2 | terminated | Nov 27, 2019 | Epizyme, Inc. | The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in… | Safety / toxicity |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | Phase 2 | terminated | Jan 9, 2023 | Thomas Jefferson University | Loss of required MRI resources needed to conduct protocol-specified procedures | Other (stated, no rule matched) |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With… | Phase 1 | terminated | Apr 20, 2016 | Regeneron Pharmaceuticals | Due to a Dose Limiting Toxicity. | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With… | Phase 2 | terminated | Nov 26, 2013 | Exelixis | Sponsor decided to close the study prior to completion of enrollment. This was a business decision… | Safety / toxicity |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in… | — | terminated | Apr 4, 2024 | Mayo Clinic | Closed to consolidate enrollment under another related study | Enrollment / accrual |
| NCT05064111 | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | — | suspended | Oct 1, 2021 | University of Arizona | Per PI, the project start is on suspension. | Other (stated, no rule matched) |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate… | Phase 1 | terminated | Sep 8, 2021 | Roswell Park Cancer Institute | PI closed study | Other (stated, no rule matched) |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | Phase 2 | withdrawn | Jun 2, 2021 | Northwestern University | Study aborted | Other (stated, no rule matched) |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC | Phase 1 | terminated | Jan 3, 2019 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy… | Phase 2 | terminated | Nov 5, 2020 | National Cancer Institute (NCI) | Insufficient drug supply | Drug supply |
| NCT05276492 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find… | Phase 1 | terminated | Mar 11, 2022 | University of Chicago | Closed by PI due to not meeting primary endpoint | Other (stated, no rule matched) |
| NCT03503097 | Genetic Testing for Men With Metastatic Prostate Cancer(GENTleMEN) | — | terminated | Apr 19, 2018 | University of Washington | Study closed to accrual before meeting enrollment goal due to end of funding. | Enrollment / accrual |
| NCT03284346 | Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer… | N/A | terminated | Sep 15, 2017 | University of Southern California | PI left | Investigator |
| NCT04996849 | Contemporary Characteristics of Penile Cancer | — | terminated | Aug 9, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of… | Phase 2 | withdrawn | Jul 30, 2024 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic… | Phase 2 | suspended | Jul 6, 2022 | Emory University | Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored… | Enrollment / accrual |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With… | Phase 1 | terminated | Feb 17, 2023 | Emory University | To review the safety data. | Safety / toxicity |
| NCT03485794 | Collection of Blood in Studying Metabolites in Patients With Prostate Cancer | — | terminated | Apr 2, 2018 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials